Advertisement

Neurologic Emergencies from Recreational Substances

  • Kaitlyn Barkley
  • Christopher P. RobinsonEmail author
Chapter

Abstract

Recreational substances have been used by humans to attain an altered state of consciousness for thousands of years. These drugs can be classified into three main categories: stimulants, depressants, and hallucinogens. Although significant overlap exists between categories, delineating the substances in this manner helps classify their physiological effects and treatment strategies for overdose and withdrawal. Stimulants activate the central nervous system and include substances like caffeine, nicotine, cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), and cathinones. Cardinal features of stimulant use include agitation and sympathomimetic effects. Depressants inhibit the central nervous system and include alcohol, opiates, cannabinoids, gamma-hydroxybutyric acid (GHB), and inhalants. The effects of depressants include lethargy and psychomotor retardation. Hallucinogens are associated with both stimulant and depressant effects and the primary feature of hallucinations. These drugs include lysergic acid diethylamide (LSD), phencyclidine (PCP), mescaline, psilocybin, and N,N-dimethyltryptamine (DMT). Recreational drug use can present with multiple neurologic complications including altered mental status, stroke, intracranial hemorrhage, seizure, or hyperthermia. Identifying a patient who has abused drugs can be vital to effective treatment.

Keywords

Alcohol Cannabis Cocaine Drugs Intoxication Methamphetamine Phencyclidine Withdrawal 

References

  1. 1.
    Guerra-Doce E. Psychoactive substances in prehistoric times: examining the archaeological evidence. Time and Mind. 2015;8(1):91–112.CrossRefGoogle Scholar
  2. 2.
    NIDA. (2015). Nationwide trends. Retrieved from https://www.drugabuse.gov/publications/drugfacts/nationwide-trends on 2018, May 14.
  3. 3.
    Zimmerman JL. Cocaine intoxication. Crit Care Clin. 2012;28(4):517–26.CrossRefGoogle Scholar
  4. 4.
    Banks ML, Worst TJ, Rusyniak DE, Sprague JE. Synthetic cathinones (“bath salts”). J Emerg Med. 2014;46(5):632–42.CrossRefGoogle Scholar
  5. 5.
    Pohorecky LA, Brick J. Pharmacology of ethanol. Pharmacol Ther. 1988;36(2):335–427.CrossRefGoogle Scholar
  6. 6.
    Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219–27.CrossRefGoogle Scholar
  7. 7.
    Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid–related illnesses and deaths. N Engl J Med. 2015;373(2):103–7.CrossRefGoogle Scholar
  8. 8.
    Salzman M, Jones CW, Rafeq R, Gaughan J, Haroz R. Epidemiology of opioid-related visits to US Emergency Departments, 1999–2013: A retrospective study from the NHAMCS (National Hospital Ambulatory Medical Care Survey). Am J Emerg Med. 2019. pii: S0735-6757(19)30218-9. [Epub ahead of print].Google Scholar
  9. 9.
    Bohnert ASB, Ilgen MA. Understanding links among opioid use, overdose, and suicide. N Engl J Med. 2019;380(1):71–9.CrossRefGoogle Scholar
  10. 10.
    Büttner A, Mall G, Penning R, Weis S. The neuropathology of heroin abuse. Forensic Sci Int. 2000;113(1):435–42.CrossRefGoogle Scholar
  11. 11.
    Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med. 2016;130(1):127–38.CrossRefGoogle Scholar
  12. 12.
    P Busardo F, W Jones A. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol. 2015;13(1):47–70.CrossRefGoogle Scholar
  13. 13.
    Howard MO, Bowen SE, Garland EL, Perron BE, Vaughn MG. Inhalant use and inhalant use disorders in the United States. Addict Sci Clin Pract. 2011;6(1):18.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Carhart-Harris RL, Kaelen M, Bolstridge M, Williams TM, Williams LT, Underwood R, Feilding A, Nutt DJ. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 2016;46(7):1379–90.CrossRefGoogle Scholar
  15. 15.
    Lodge D, Mercier MS. Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol. 2015;172(17):4254–76.CrossRefGoogle Scholar
  16. 16.
    Halpern JH. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther. 2004;102(2):131–8.CrossRefGoogle Scholar
  17. 17.
    Behrouz R, Godoy DA, Azarpazhooh MR, Di Napoli M. Altered mental status in the neurocritical care unit. J Crit Care. 2015;30(6):1272–7.CrossRefGoogle Scholar
  18. 18.
    Silver B, Miller D, Jankowski M, Murshed N, Garcia P, Penstone P, Straub M, Logan SP, Sinha A, Morris DC, Katramados A. Urine toxicology screening in an urban stroke and TIA population. Neurology. 2013;80(18):1702–9.17.CrossRefGoogle Scholar
  19. 19.
    Jauch EC, Saver JL, Adams HP, Bruno A, Demaerschalk BM, Khatri P, McMullan PW, Qureshi AI, Rosenfield K, Scott PA, Summers DR. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.CrossRefGoogle Scholar
  20. 20.
    Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, Johnston KC, Johnston SC, Khalessi AA, Kidwell CS, Meschia JF. 2015 American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(10):3020–35.CrossRefGoogle Scholar
  21. 21.
    Alldredge BK, Lowenstein DH, Simon RP. Seizures associated with recreational drug abuse. Neurology. 1989;39(8):1037–1037.CrossRefGoogle Scholar
  22. 22.
    Ziu M, Dengler B, CorDell D, Bartanusz V. Diagnosis and management of primary pyogenic spinal infections in intravenous recreational drug users. Neurosurg Focus. 2014;37(2):E3.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of NeurosurgeryUniversity of FloridaGainesvilleUSA
  2. 2.Department of NeurologyUniversity of FloridaGainesvilleUSA

Personalised recommendations